Bavarian, BioMedica Call Vaccine Patent Truce

Law360, New York (January 27, 2010, 12:40 PM EST) -- Foes no longer, Bavarian Nordic A/S and Oxford BioMedica PLC have entered cross-licensing agreements as part of a global settlement ending allegations that BioMedica’s experimental cancer drug filches Bavarian’s patented vaccine technology.

The parties announced Wednesday that fruitful settlement discussions have set the stage for future collaboration between the one-time rivals now that Bavarian has dropped its infringement action and BioMedica has withdrawn its challenges to the patents at the European Patent Office.

In July 2008 Denmark-based Bavarian Nordic filed suit in the U.S. District Court...
To view the full article, register now.